<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01341405</url>
  </required_header>
  <id_info>
    <org_study_id>CG100649-2-02</org_study_id>
    <nct_id>NCT01341405</nct_id>
  </id_info>
  <brief_title>Study of CG100649 Versus Celecoxib in Osteoarthritis Patients</brief_title>
  <official_title>A Double-blind, Randomized, Multicenter, Noninferiority, Phase II Repeat Dose Study of CG100649 Versus Celecoxib in Osteoarthritis Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CrystalGenomics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CrystalGenomics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double-blind, randomized, multicenter, phase 2b, noninferiority comparison of two&#xD;
      active dose levels of CG100649 vs. a standard anti-arthritic dose of celecoxib (Celebrex).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a double-blind, randomized, multicenter, noninferiority, phase 2 study. Subjects will&#xD;
      discontinue current medications (NSAID or COX-2 inhibitor) 5-14 days prior to randomization.&#xD;
      Paracetamol (acetaminophen; â‰¤2 gm/day) may be used for breakthrough pain. Other NSAIDs, COX-2&#xD;
      inhibitors, opioids, and corticosteroids may not be used at any time during this study. Only&#xD;
      subjects recording average WOMAC pain score of 4 to 8 on a 0-10 numerical rating scale during&#xD;
      the washout period and meeting all other inclusion criteria will be randomized into the&#xD;
      study.&#xD;
&#xD;
      Male and female adults, ages 20 and older, with a history of osteoarthritis (OA) of the knee&#xD;
      or hip diagnosed by radiograph obtained within the past 20 years and with pain at least 3&#xD;
      months from OA can participate in this study. OA must be confirmed by radiographs and&#xD;
      diagnosed according to American College of Rheumatology (ACR) guidelines. Subjects must&#xD;
      qualify as ACR global functional status I, II, or III (excluding IV) and Kellgren-Lawrence&#xD;
      grade 1, 2 or 3 (excluding grade 4).&#xD;
&#xD;
      Subjects meeting screening criteria will be randomized to receive 28 days dosing of an active&#xD;
      dose of CG100649 or comparator (celecoxib).&#xD;
&#xD;
      Antiarthritic efficacy will be evaluated by changes in the Western Ontario and McMaster&#xD;
      Universities (WOMAC) OA index completed on Day 1 (Baseline) and on Days 14, 28 and 42. The&#xD;
      WOMAC pain subscale will be evaluated at screening and on Days 1, 7, 14, 21, 28, 35 and 42.&#xD;
&#xD;
      All doses will be administered orally once daily in the morning. There are 3 planned&#xD;
      treatment arms (2 with active compound + one comparator (celecoxib) group) with n=44 per&#xD;
      treatment arm. Total number of subjects will be 132.&#xD;
&#xD;
      Treatment A: CG100649: 2 mg/day (Days 1-28); Treatment B: CG100649: 4 mg/day (Days 1-28);&#xD;
      Treatment C: celecoxib: 200 mg/day (Days 1-28); Active and comparator medications will have&#xD;
      identical appearance.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>WOMAC pain subscale</measure>
    <time_frame>Day 28</time_frame>
    <description>The primary endpoint will be the change in &quot;Pain&quot; (average WOMAC-Pain score in the index joint) at Day 28 vs. Baseline (Day 1 using the ITT population).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time course for change in WOMAC OA Index</measure>
    <time_frame>Days 14, 28, 42</time_frame>
    <description>Change in the sum of the WOMAC OA Index on Days 14, 28 and 42 vs. pre-dose Baseline WOMAC (repeated measures ANOVA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course for change in WOMAC stiffness &amp; function subscales</measure>
    <time_frame>Days 14, 28, 42</time_frame>
    <description>Change in subscales of WOMAC assessment (stiffness, physical function) on Days 14, 28 and 42 vs. Baseline WOMAC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time course for change in WOMAC pain subscale</measure>
    <time_frame>Days 7, 14, 21, 28, 35, and 42</time_frame>
    <description>Change in the &quot;Pain&quot; subscale on Days 7, 14, 21, 28, 35 and 42 vs. pre-dose Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject's Global Assessment</measure>
    <time_frame>Days 1, 14, 28, and 42</time_frame>
    <description>Subject's Global Assessment (&quot;How Do You Feel?&quot;)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician's Global Assessment</measure>
    <time_frame>Days 1, 14, 28, and 42</time_frame>
    <description>Physician's Global Assessment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Withdrawals</measure>
    <time_frame>Day 28</time_frame>
    <description>Withdrawals due to lack of analgesic efficacy or non-compliance rates</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in use of rescue medication</measure>
    <time_frame>Day 28</time_frame>
    <description>Change in total paracetamol used for rescue medication</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">125</enrollment>
  <condition>Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>CG100649 2 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsule, once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CG100649 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>capsule, 4 mg, once daily for 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>celecoxib 200 mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>capsule, once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG100649</intervention_name>
    <description>capsule, 2 mg, once daily for 28 days</description>
    <arm_group_label>CG100649 2 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Celecoxib</intervention_name>
    <description>capsule, celecoxib 200 mg, once daily for 28 days</description>
    <arm_group_label>celecoxib 200 mg</arm_group_label>
    <other_name>Celebrex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CG100649</intervention_name>
    <description>capsule, 4 mg, once daily for 28 days</description>
    <arm_group_label>CG100649 4 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Males and females, age 20 years old and more, able and willing to provide written&#xD;
             informed consent to participate in the study&#xD;
&#xD;
          2. Confirmed osteoarthritis (OA) of the knee or hip by radiograph obtained within the&#xD;
             past 20 years and diagnosed according to American College of Rheumatology (ACR)&#xD;
             guidelines.&#xD;
&#xD;
          3. Subject must have pain at least 3 month duration from osteoarthritis (OA)&#xD;
&#xD;
          4. Normal blood pressure (BP) [systolic BP 90-140 mmHg, diastolic BP 50-90 mmHg] and&#xD;
             heart rate (HR) [resting 45-90 beats per minute (bpm)]&#xD;
&#xD;
          5. Subjects with hypertension should have stably taken ACE inhibitor, angiotensin II&#xD;
             receptor (type AT1) antagonist, beta-blocker and/or diuretics at least 3 months at the&#xD;
             time of screening in order to keep normal blood pressure. Subjects should not change&#xD;
             or stop hypertension drug during the study.&#xD;
&#xD;
          6. Clinical Chemistry must be within 2x normal limits&#xD;
&#xD;
          7. Urinalysis must be within normal range.&#xD;
&#xD;
          8. Prior to randomization on Day 1, the mean WOMAC pain score in the index joint must be&#xD;
             between 4 and 8 on a 0-10 numerical rating scale.&#xD;
&#xD;
          9. Subjects and their sexual partners must agree to use double barrier contraception&#xD;
             during the study period and for 3 months afterwards or provide proof of surgical&#xD;
             sterility or post-menopause more than 1 year.&#xD;
&#xD;
         10. Subject must be able to read and understand and follow the study instructions.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Use of any analgesics except the study medication or paracetamol (acetaminophen) at&#xD;
             any time during this study;&#xD;
&#xD;
          2. Use of corticosteroids or intra-articular viscosupplementation within 3 months of&#xD;
             screening;&#xD;
&#xD;
          3. Use of antidepressants or anticonvulsants within 2 months of screening;&#xD;
&#xD;
          4. Cognitive or psychiatric disorders, or daytime use of medications (alcohol,&#xD;
             benzodiazepines, barbiturates, muscle relaxants) that could diminish compliance with&#xD;
             study procedures;&#xD;
&#xD;
          5. Use of anticoagulants (aspirin, warfarin, heparin) within 2 weeks of screening;&#xD;
&#xD;
          6. Use of any medications that will affect pain perception (e.g. tranquilizers,&#xD;
             hypnotics);&#xD;
&#xD;
          7. Hypersensitivity to non-steroidal anti-inflammatory drugs (NSAIDs), cyclooxygenase&#xD;
             (COX)-2 inhibitors, or carbonic anhydrase inhibitors;&#xD;
&#xD;
          8. Use of oriental medicine (herbal medicine) or glucosamine within 14 days of dose&#xD;
             administration&#xD;
&#xD;
          9. History of drug or alcohol abuse within one year prior to screening;&#xD;
&#xD;
         10. Known allergy or hypersensitivity to sulfa drugs;&#xD;
&#xD;
         11. History of congestive heart failure, ischemic heart disease, peripheral arterial&#xD;
             disease, cerebrovascular disease or subjects who have one of these diseases;&#xD;
&#xD;
         12. Use of chemotherapy agents or history of cancer, other than non-metastatic skin cancer&#xD;
             that has been completely excised, within five (5) years prior to the screening visit;&#xD;
&#xD;
         13. Subjects with gout, pseudogout, inflammatory arthritis, Paget's disease, chronic pain&#xD;
             syndrome, fibromyalgia, or another major joint disease;&#xD;
&#xD;
         14. Subjects requiring knee or hip arthroplasty within 2 months of screening or&#xD;
             anticipating any need for a surgical procedure on the index joint during the study;&#xD;
&#xD;
         15. Subjects who have had surgery on the affected joint within 6 months of screening and&#xD;
             subjects with a prosthesis at the index joint;&#xD;
&#xD;
         16. History of seizure disorder;&#xD;
&#xD;
         17. Subjects with serious psychosocial co-morbidities;&#xD;
&#xD;
         18. Subjects with gastrointestinal, renal, hepatic, or coagulant disorder within 6 months&#xD;
             of screening;&#xD;
&#xD;
         19. Esophageal or duodenal ulcer within 6 months of screening;&#xD;
&#xD;
         20. History of nasal polyps, bronchospasm, and urticaria;&#xD;
&#xD;
         21. Pregnant or breast-feeding;&#xD;
&#xD;
         22. Subject with genetic problem of galactose intolerance, Lapp lactose deficiency or&#xD;
             glucose-galactose malabsorption (because celecoxib contains lactose)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Myung Chul Lee, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Seoul National University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Seong-Il Bin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Asan Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jong-Oh Kim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ewha Womans University Mokdong Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Chong Hyuk Choi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gangnam Severance Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hong Chul Lim, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Korea University Guro Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>October 2012</verification_date>
  <study_first_submitted>April 22, 2011</study_first_submitted>
  <study_first_submitted_qc>April 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2011</study_first_posted>
  <last_update_submitted>October 9, 2012</last_update_submitted>
  <last_update_submitted_qc>October 9, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Celecoxib</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>April 29, 2013</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>January 26, 2016</submitted>
    <returned>February 22, 2016</returned>
    <submitted>June 24, 2016</submitted>
    <returned>August 4, 2016</returned>
    <submitted>August 17, 2016</submitted>
    <submission_canceled>Unknown</submission_canceled>
    <submitted>August 28, 2016</submitted>
    <returned>October 19, 2016</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

